Fast Five Quiz: Advanced and Metastatic Prostate Cancer Presentation and Diagnosis

Daniel S. Schwartz, MD, MBA


June 27, 2022

In patients with a Gleason score of > 6 at initial presentation, a bone scan may be indicated regardless of PSA level. However, the value of a bone scan is limited in patients with a Gleason score of < 7 and a PSA level of < 20 ng/mL, per Terris and colleagues. The National Comprehensive Cancer Network (NCCN) guidelines note that multiparametric MRI (mpMRI) outperforms bone scan for detection of bone metastases.

Activity in a bone scan may not be observed until 5 years after micrometastasis has occurred; as such, negative bone scan results do not exclude metastasis.

Chest radiography can be used both as a baseline study and, in select cases, to help reveal rare pulmonary metastases.

Immunoscintigraphy to reveal extraprostatic disease (ie, localized recurrence or lymphatic spread) may yield false-negative results, but the specificity of these studies may be improved when they are combined with CT scanning or single-photon emission CT scanning.

Learn more about imaging studies for the diagnosis of advanced or metastatic prostate cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.